HUTCHMED (CHINA) LIMITED - AMERICAN DEPOSITARY SHA

HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China

20 أغسطس 2023 20:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Reports 2023 Interim Results and Provides Business Updates

31 يوليو 2023 07:41:53 بحسب Nasdaq GlobeNewswire

HUTCHMED Receives Breakthrough Therapy Designation in China for Fruquintinib Combination with Sintilimab for Treatment of Advanced Endometrial Cancer, and Completes Enrollment of Registration Study

19 يوليو 2023 20:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Announces Changes to Board of Directors and Technical Committee 

13 يوليو 2023 04:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China

09 يوليو 2023 20:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED to Announce 2023 Half-Year Financial Results

26 يونيو 2023 04:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED and Takeda Announce Publication of Phase III FRESCO-2 Results in The Lancet

15 يونيو 2023 20:30:00 بحسب Nasdaq GlobeNewswire

Takeda and HUTCHMED Announce Marketing Authorization Application of Fruquintinib for Previously Treated Metastatic Colorectal Cancer Validated by the European Medicines Agency

15 يونيو 2023 10:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Highlights Presentations for Hematological Malignancy Programs at the 2023 EHA and ICML Meetings

09 يونيو 2023 05:30:00 بحسب Nasdaq GlobeNewswire

Takeda and HUTCHMED Announce New Drug Application (NDA) for Fruquintinib for Treatment of Previously Treated Metastatic Colorectal Cancer Granted Priority Review

25 مايو 2023 19:00:54 بحسب Nasdaq GlobeNewswire

HUTCHMED Highlights Presentations at the 2023 ASCO Annual Meeting

25 مايو 2023 18:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Announces Board of Directors and Board Committee Membership

12 مايو 2023 04:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Announces Appointment of Independent Non-executive Director and Member of Board Committees 

10 مايو 2023 04:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Announces NDA Acceptance in China for Fruquintinib in Second-Line Gastric Cancer

17 أبريل 2023 20:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Highlights Presentations at American Association for Cancer Research Annual Meeting 2023

11 أبريل 2023 20:00:00 بحسب Nasdaq GlobeNewswire

Intended Retirement of Independent Non-executive Director

11 أبريل 2023 04:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Initiates Registration Phase Enrollments of HMPL-453 for IHCC and Savolitinib for Gastric Cancer following NMPA Consultations

04 أبريل 2023 05:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Completes Rolling Submission of NDA to U.S. FDA for Fruquintinib for the Treatment of Refractory Metastatic Colorectal Cancer

30 مارس 2023 20:00:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Announces Closing of Fruquintinib License to Takeda Outside China

14 مارس 2023 09:30:00 بحسب Nasdaq GlobeNewswire

HUTCHMED Confirms No Assets Held at Silicon Valley Bank

12 مارس 2023 20:07:31 بحسب Nasdaq GlobeNewswire